Stocks making the biggest moves midday: Snap, McCormick & Co, Rocket Lab, Apellis, Marvell & more

Multiple corporate events drove large stock moves: Snap surged ~12% after activist Irenic disclosed a roughly 2.5% stake and proposed shuttering Snap's AR Specs; Apellis jumped 135% after Biogen agreed to buy it for $5.6B cash and Centessa rallied 45% on Eli Lilly's acquisition. FactSet beat Q2 adjusted EPS $4.46 vs $4.38 consensus and raised FY adjusted EPS guidance to $17.25–$17.75, while Constellation Energy cut 2026 EPS to $11–$12 (FactSet consensus $11.73), sending shares down >8%. Other notable moves: Marvell +7% after Nvidia committed $2B; McCormick fell >5% on a nearly $45B deal for Unilever's food business (including $15.7B cash); Rocket Lab, Symbotic and Amphenol saw positive stock reactions tied to M&A, strategic deals or an analyst upgrade.

Analysis

Activist pressure at SNAP is the obvious near-term catalyst, but the higher-conviction lever is cash-flow redeployment: shuttering a capital-intensive AR hardware line could free ~$200–400m of annualized spend (multi-year estimate based on comparable AR efforts) and reaccelerate ad product investment. That reallocation amplifies upside not just for Snap but for ad-tech partners and auction dynamics—expect higher CPMs and improved yield curves within 6–12 months if buybacks or higher ad ROI follow.

The Marvell–Nvidia tie-up and Rocket Lab’s Mynaric clearance signal a wave of vertical consolidation across compute, networking and space-optics where strategic capital (Nvidia’s $2bn) is being used as both growth capex and defensive supply anchoring; Marvell is de-risked structurally but remains execution-sensitive to China export policy over the next 3–12 months. Symbotic’s AWG win is a microcosm of regionally-stepped automation adoption: if similar rollouts scale, expect incremental reorder cycles for robotics integrators and component suppliers over the next 12–36 months — a small but durable revenue base shift.

Constellation’s disappointing guide is a leading indicator of renewed price pressure in the market for large-scale data-center energy contracts; this raises negotiation leverage for hyperscalers and could compress utility-margin tails over 6–18 months. Finally, the biotech M&A spate (Biogen/Apellis, Lilly/Centessa) reprices takeover comps and narrows windows for opportunistic buys — acquirer share selloffs create short-term dislocations but longer-term portfolio concentration risk for buyers.

Key Decisions for Investors

• Long SNAP (6–12 month call spread): buy 6–12m calls 15% OTM and sell 35% OTM to finance — target asymmetric 2.5x gross upside if activist secures board concessions or asset sale within 6–12 months; max loss = premium paid (~<3% notional).
• Long MRVL (2–9 months): buy equity sized for 4–6% portfolio exposure ahead of NVDA strategic integration milestones; upside if NVDA commits capital/tech integration (~20–40% IRR scenario), tail risk = regulatory/China export friction, hedge with 3–6 month puts at 12–15% OTM (cost 1–2% notional).
• Long SYM and APH pair (12–24 months): allocate long SYM (robotics revenue growth) and long APH as supply-chain beneficiary with 60/40 split (SYM larger). Expect outsized revenue re-rates if automation rollouts accelerate — set stop loss at 20% drawdown for each name.
• Short CEG (3–12 months): initiate small, conviction-weighted short or buy OTM puts after re-test of weak guidance narrative; thesis: persistent margin compression on new data-center deals and rate-sensitive capex will keep FY upside limited — target 30–45% downside if guidance underruns persist, cap position sizing to limit fund-level exposure.
• Event-monitor list for biotech arbitrage (0–6 months): avoid picking up acquirer stock immediately (BIIB) without hedges; consider selling short-dated volatility or buying protective puts on acquirers that gap down post-announcement, capturing 10–25% expected mean-reversion while capping premium spend.